Cancer Drug Classifications

Last updated: 2020-12-24

0.1 Introduction

Drug Classification Challenges:

• Clinically relevant classification for data collection and analysis purposes
  
• Interoperability across consortia, including ASCO

0.2 Reingold-Tilford Tree Diagrams

0.2.1 Antibody Drug Conjugates

0.2.1.1 Without Siblings

0.2.1.2 With Siblings

0.2.2 Cellular Therapy

0.2.2.1 Without Siblings

0.2.2.2 With Siblings

0.2.3 Checkpoint Inhibitors

0.2.3.1 Without Siblings

0.2.3.2 With Siblings

0.2.4 Cytotoxic Chemotherapy

0.2.4.1 Without Siblings

0.2.4.2 With Siblings

0.2.5 Endocrine Therapy

0.2.5.1 Without Siblings

0.2.5.2 With Siblings

0.2.6 Immunomodulators and Immunostimulants

0.2.6.1 Without Siblings

0.2.6.2 With Siblings

0.2.7 Intravesicular Therapy

0.2.7.1 Without Siblings

0.2.7.2 With Siblings

0.2.8 Monoclonal Antibody Targeted Therapy

0.2.8.1 Without Siblings

0.2.8.2 With Siblings

0.2.9 Other Immunotherapy

0.2.9.1 Without Siblings

0.2.9.2 With Siblings